<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Tumors of female reproductive system</journal-id><journal-title-group><journal-title xml:lang="en">Tumors of female reproductive system</journal-title><trans-title-group xml:lang="ru"><trans-title>Опухоли женской репродуктивной системы</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1994-4098</issn><issn publication-format="electronic">1999-8627</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1239</article-id><article-id pub-id-type="doi">10.17650/1994-4098-2024-16-2-83-89</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>GYNECOLOGY. ORIGINAL REPORTS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ГИНЕКОЛОГИЯ. ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Tumour budding, MELF-pattern and tumour-infiltrating lymphocytes as possible pathomorphological parameters of the course of endometrioid adenocarcinoma of the uterine corpus</article-title><trans-title-group xml:lang="ru"><trans-title>Опухолевое почкование, MELF-паттерн и опухоль-инфильтрирующие лимфоциты как возможные патоморфологические параметры течения эндометриоидной аденокарциномы тела матки</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3808-8832</contrib-id><name-alternatives><name xml:lang="en"><surname>Zinovkin</surname><given-names>D. A.</given-names></name><name xml:lang="ru"><surname>Зиновкин</surname><given-names>Д. А.</given-names></name></name-alternatives><address><country country="BY">Belarus</country></address><bio xml:lang="en"><p>Dmitriy Alexandrovich Zinovkin</p><p>5 Lange St., Gomel 246000</p></bio><bio xml:lang="ru"><p>Дмитрий Александрович Зиновкин</p><p>246000 Гомель, ул. Ланге, 5</p></bio><email>zinovkin_da@gsmu.by</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9935-691X</contrib-id><name-alternatives><name xml:lang="en"><surname>Veyalkin</surname><given-names>I. V.</given-names></name><name xml:lang="ru"><surname>Веялкин</surname><given-names>И. В.</given-names></name></name-alternatives><address><country country="BY">Belarus</country></address><bio xml:lang="en"><p>290 Ilyicha St., Gomel 246040</p></bio><bio xml:lang="ru"><p>246040 Гомель, ул. Ильича, 290</p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0977-5481</contrib-id><name-alternatives><name xml:lang="en"><surname>Achinovich</surname><given-names>S. L.</given-names></name><name xml:lang="ru"><surname>Ачинович</surname><given-names>С. Л.</given-names></name></name-alternatives><address><country country="BY">Belarus</country></address><bio xml:lang="en"><p>2 Meditsinskaya St., Gomel 246012</p></bio><bio xml:lang="ru"><p>246012 Гомель, ул. Медицинская, 2</p></bio><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0002-8361-0260</contrib-id><name-alternatives><name xml:lang="en"><surname>Slepokurova</surname><given-names>I. I.</given-names></name><name xml:lang="ru"><surname>Слепокурова</surname><given-names>И. И.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>5 Lange St., Gomel 246000</p></bio><bio xml:lang="ru"><p>246000 Гомель, ул. Ланге, 5</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8465-9368</contrib-id><name-alternatives><name xml:lang="en"><surname>Lyzikova</surname><given-names>Yu. A.</given-names></name><name xml:lang="ru"><surname>Лызикова</surname><given-names>Ю. А.</given-names></name></name-alternatives><address><country country="BY">Belarus</country></address><bio xml:lang="en"><p>5 Lange St., Gomel 246000</p></bio><bio xml:lang="ru"><p>246000 Гомель, ул. Ланге, 5</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0002-4616-0870</contrib-id><name-alternatives><name xml:lang="en"><surname>Farooq</surname><given-names>A.</given-names></name><name xml:lang="ru"><surname>Фарук</surname><given-names>А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>5 Lange St., Gomel 246000</p></bio><bio xml:lang="ru"><p>246000 Гомель, ул. Ланге, 5</p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Gomel State Medical University</institution></aff><aff><institution xml:lang="ru">УО «Гомельский государственный медицинский университет»</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Republican Scientific and Practical Centre of Radiation Medicine and Human Ecology</institution></aff><aff><institution xml:lang="ru">УЗ «Республиканский научно-практический центр  радиационной медицины и экологии человека»</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Gomel Regional Clinical Oncological Dispensary</institution></aff><aff><institution xml:lang="ru">У «Гомельский областной клинический онкологический диспансер»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2024-07-29" publication-format="electronic"><day>29</day><month>07</month><year>2024</year></pub-date><volume>20</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>83</fpage><lpage>89</lpage><history><date date-type="received" iso-8601-date="2024-07-29"><day>29</day><month>07</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2024-07-29"><day>29</day><month>07</month><year>2024</year></date></history><permissions><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://ojrs.abvpress.ru/ojrs/article/view/1239">https://ojrs.abvpress.ru/ojrs/article/view/1239</self-uri><abstract xml:lang="en"><p><bold>Aim</bold>. To evaluatethe role tumour budding (TB), MELF-pattern and tumour-infiltrating lymphocytes (TILs) as possible prognostic factors of endometrioid adenocarcinoma of the uterine corpus.</p><p><bold>Materials and methods</bold>. A single-centre, retrospective, observational study was conducted involving 188 patients with endometrioid adenocarcinoma of the uterine body. 40 patients who had disease recurrence or died directly from progression of endometrioid adenocarcinoma of the uterine body were the unfavourable outcome group, 148 patients without progression and death from this tumour were the favourable outcome group. Fisher, Yates exact two-sided criteria were used to analyze the data. Survival analysis was performed using <italic>log-rank</italic> test. The hazard ratio (HR) and its 95 % confidence interval (CI) were estimated using single-factor analysis with <italic>log-rank</italic> test and multivariate Cox proportional hazards analysis. <italic>p </italic>&lt;0.05 was considered statistically significant.</p><p><bold>Results.</bold> TB was observed predominantly in the group of patients with unfavourable outcome (<italic>р</italic> &lt;0.0001) Survival analysis revealed statistically significant decreased survival in cases with TB (HR 5.3; 95 % CI 2.2–12.7; <italic>р </italic>&lt;0.0001)<bold>. </bold>MELF-pattern was statistically significantly more frequent in the group of patients with unfavourable outcome (<italic>р </italic>&lt;0.0001), a decreased survival of patients was observed in the presence of MELF-pattern (HR 5.8; 95 % CI 2.1–16.2; <italic>р </italic>&lt;0.0001). Comparison of groups according to the number of TILs revealed statistically significant differences (р = 0.0242). When analyzing survival relative to the threshold value of the number of TILs, statistically significant differences were also observed (HR 3.7; 95 % CI 1.7–7.9; <italic>р</italic> = 0.021). Multivariate Cox proportional hazards analysis revealed that only TB and MELF-pattern had prognostic significance for recurrence-free survival (HR 3.7; 95 % CI 1.8–7.4;<italic> р</italic> &lt;0.001).</p><p><bold>Conclusion</bold>. TB and MELF-pattern are specific changes in the stroma of endometrioid adenocarcinoma stroma of the uterine corpus that can be used as pathomorphological predictors of clinical outcome.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Цель исследования</bold> – оценка роли опухолевого почкования (ОП), MELF-паттерна и опухоль-инфильтрирующих лимфоцитов (ОИЛ) как возможных факторов прогноза эндометриоидной аденокарциномы тела матки.</p><p><bold>Материалы и методы. </bold>Было проведено одноцентровое ретроспективное обсервационное исследование с участием 188 пациенток с эндометриоидной аденокарциномой тела матки. 40 пациенток, имевших рецидивы заболевания либо умерших непосредственно от прогрессии эндометриоидной аденокарциномы тела матки, составили группу с неблагоприятным исходом, 148 пациенток, у которых не отмечалось прогрессирования заболевания и смерти от данной опухоли, – группу с благоприятным исходом. Для анализа данных использовались точный двусторонний критерий Фишера, критерий Йетса. Анализ выживаемости проводили с использованием <italic>log-rank</italic>-теста. Оценивали отношение рисков (hazard ratio, HR) и его 95 % доверительный интервал (ДИ) c использованием однофакторного анализа при проведении <italic>log-rank</italic>-теста и многофакторного анализа пропорциональных рисков Кокса. Статистически значимым принимали <italic>р</italic>&lt;0,05.</p><p><bold>Результаты</bold>. ОП наблюдалось преимущественно в группе пациенток с неблагоприятным исходом (<italic>р</italic>&lt;0,0001). Анализ выживаемости выявил статистически значимое снижение выживаемости в случае наличия ОП (HR 5,3; 95 % ДИ 2,2–12,7;<bold> </bold><italic>р</italic>&lt;0,0001). MELF-паттерн статически значимо чаще отмечался в группе пациенток с неблагоприятным исходом (<italic>р</italic>&lt;0,0001). Сравнение групп по количеству ОИЛ выявило статистически значимые различия (<italic>р</italic>=0,0242). При анализе выживаемости относительно порогового значения количества ОИЛ также отмечались статистически значимые различия (HR 3,7; 95 % ДИ 1,7–7,9; <italic>р</italic> = 0,021). Многофакторный анализ пропорциональных рисков Кокса выявил, что только ОП и MELF-паттерн имели прогностическое значение для безрецидивной выживаемости (HR 3,7; 95 % ДИ 1,8–7,4; <italic>р</italic>&lt;0,001и HR 3,2; 95 % ДИ 1,6–6,5; <italic>р</italic>&lt;0,001).</p><p><bold>Выводы.</bold> ОП и MELF-паттерн являются специфическими изменениями стромы эндометриоидной аденокарциномы тела матки, которые могут быть использованы в качестве патоморфологических предикторов клинического течения заболевания.</p></trans-abstract><kwd-group xml:lang="en"><kwd>tumor budding</kwd><kwd>MELF-pattern</kwd><kwd>tumor infiltrating lymphocytes</kwd><kwd>endometrioid adenocarcinoma of the uterine corpus</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>опухолевое почкование</kwd><kwd>MELF-паттерн</kwd><kwd>опухоль-инфильтрирующие лимфоциты</kwd><kwd>эндометриоидная аденокарцинома тела матки</kwd></kwd-group><funding-group><funding-statement xml:lang="en">The study was performed within the framework of the grant BRFFR-NNSFC No. 20230285 dated 10 March, 2023 “Vasculogenic mimicry and proangiogenic activity in the tumour microenvironment under the action of vCAF in endometrial cancer”.</funding-statement><funding-statement xml:lang="ru">Работа была выполнена в рамках гранта БРФФИ-НФЕНK № 20230285 от 10.03.2023 «Васкулогенная мимикрия и проангиогенная активность в опухолевом микроокружении под действием vCAF при раке эндометрия».</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Sung H., Ferlay J., Siegel R.L. et al. Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin 2021;71:209–49. DOI: 10.3322/caac.21660</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Watkins J.C., Downing M.J., Crous-Bou M. et al. Endometrial tumor classification by histomorphology and biomarkers in the nurses’ health study. J Cancer Epidemiol 2021;2021:1–9. DOI: 10.1155/2021/8884364</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Lugli A., Karamitopoulou E., Zlobec I. Tumour budding: A promising parameter in colorectal cancer. Br J Cancer 2012;106:1713–7. DOI: 10.1038/bjc.2012.127</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Huang T., Bao H., Meng Y. et al. Tumour budding is a novel marker in breast cancer: The clinical application and future prospects. Ann Med 2022;54:1303–12. DOI: 10.1080/07853890.2022.2070272</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Zlobec I., Berger M.D., Lugli A. Tumour budding and its clinical implications in gastrointestinal cancers. Br J Cancer 2020;123: 700–8. DOI: 10.1038/s41416-020-0954-z</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Qian L., Zhang J., Lu S. et al. Potential key roles of tumour budding: A representative malignant pathological feature of nonsmall cell lung cancer and a sensitive indicator of prognosis. BMJ Open 2022;12. DOI: 10.1136/bmjopen-2021-054009</mixed-citation></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">Portyanko A.S., Degtyareva M.Yu., Gorgun Yu.V. et al. Remodeling of the microtubules in the invasive front of the colorectal cancer. Lechebnoe delo = General Medicine 2012;4(26):64–9. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Портянко А.С., Дегтярева М.Ю., Горгун Ю.В. и др. Ремоделирование микротрубочек в инвазивном крае колоректального рака. Лечебное дело 2012;4(26):64–9.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><mixed-citation>Murray S.K., Young R.H. Priority for description of the MELF pattern of myoinvasive endometrioid carcinoma. Am J Surg Pathol 2017;41:1150. DOI: 10.1097/pas.0000000000000879</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Mateva S., Nikolova M., Yordanov A. Patterns of myometrial invasion in endometrial adenocarcinoma with emphasizing on microcystic, elongated and fragmented (MELF) glands pattern: A narrative review of the literature. Diagnostics 2021;11:1707. DOI: 10.3390/diagnostics11091707</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Song J., Li H., Guo H. et al. Microcystic, elongated and fragmented (MELF) pattern in endometrial carcinoma: Clinicopathologic analysis and prognostic implications. Medicine 2022;101. DOI: 10.1097/md.0000000000031369</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Zinovkin D.A., Achinovich S.L., Zubritskiy M.G. et al. High expression of galectin-1, VEGF and increased microvessel density are associated with MELF pattern in stage I–III endometrioid endometrial adenocarcinoma. J Pathol Transl Med 2019;53:280–8. DOI: 10.4132/jptm.2019.05.13</mixed-citation></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">Kiselevskiy M.V., Vlasenko R.Ya., Zabotina T.N. et al. Prognostic significance of tumor-infiltrating lymphocytes. Immunologiya = Immunology 2019;40(1):73–82. (In Russ.). DOI: 10.24411/0206-4952-2019-11009</mixed-citation><mixed-citation xml:lang="ru">Киселевский М.В., Власенко Р.Я., Заботина Т.Н. и др. Прогностическая значимость опухоль-инфильтрирующих лимфоцитов. Иммунология 2019;40(1):73–82. DOI: 10.24411/0206-4952-2019-11009</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><mixed-citation>Mendiola M., Pellinen T., Ramon-Patino J.L. et al. Prognostic implications of tumor-infiltrating T cells in early-stage endometrial cancer. Mod Pathol 2022;35:256–65. DOI: 10.1038/s41379-021-00930-7</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Willvonseder B., Stögbauer F., Steiger K. et al. The immunologic tumor microenvironment in endometrioid endometrial cancer in the morphomolecular context: mutual correlations and prognostic impact depending on molecular alterations. Cancer Immunol Immunother 2021;70:1679–89. DOI: 10.1007/s00262-020-02813-3</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Rau T.T., Bettschen E., Büchi C. et al. Prognostic impact of tumor budding in endometrial carcinoma within distinct molecular subgroups. Mod Pathol 2021;34:222–32. DOI: 10.1038/s41379-020-0626-9</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Pavlakis K., Messini I., Vrekoussis T. et al. MELF invasion in endometrial cancer as a risk factor for lymph node metastasis. Histopathology 2011;58:966–73. DOI: 10.1111/j.1365-2559.2011.03802.x</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Hendry S., Salgado R., Gevaert T. et al. Assessing tumor-infiltrating lymphocytes in solid tumors: A practical review for pathologists and proposal for a standardized method from the international immuno-oncology biomarkers working group: Part 2: TILs in melanoma, gastrointestinal tract carcinomas, non-small cell lung carcinoma and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, genitourinary carcinomas, and primary brain tumors. Adv Anat Pathol 2017;24:311–35. DOI: 10.1097/pap.0000000000000161.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Liu S., Zeng S., Xia L. et al. Tumor-infiltrating lymphocytes benefit prediction of axillary pathologic response and prognostication of event-free survival in HER2-positive and biopsy-proven nodepositive breast cancer treated with neoadjuvant therapy. Breast Cancer Res Treat 2020;185:629–38. DOI: 10.1007/s10549-020-06015-4</mixed-citation></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">Korneva Yu.S., Ukrainets R.V., Dorosevich A.E. Prognostic value of microcirculatory changes and alterations in the cellular microenvironment in patients with glandular hyperplasia of the endometrium and endometrial cancer (literature review). Opukholi zhenskoy reproduktivnoy sistemy = Tumors of Female Reproductive System 2019;15(1):67–72. (In Russ.). DOI: 10.17650/1994-4098-2019-15-1-67-72</mixed-citation><mixed-citation xml:lang="ru">Корнева Ю.С., Украинец Р.В., Доросевич А.Е. Прогностическое значение изменений микроциркуляторного русла и клеточного микроокружения при железистой гиперплазии эндометрия и раке эндометрия (обзор литературы). Опухоли женской репродуктивной системы 2019;15(1):67–72. DOI: 10.17650/1994-4098-2019-15-1-67-72</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><mixed-citation>Yamamoto M., Kaizaki Y., Kogami A. et al. Prognostic significance of tumor budding, poorly differentiated cluster, and desmoplastic reaction in endometrioid endometrial carcinomas. J Obstet Gynaecol Res 2021;47:3958–67. DOI: 10.1111/jog.14997</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Dogan Altunpulluk M., Kir G., Topal C.S. et al. The association of the microcystic, elongated and fragmented (MELF) invasion pattern in endometrial carcinomas with deep myometrial invasion, lymphovascular space invasion and lymph node metastasis. J Obstet Gynaecol 2014;35:397–402. DOI: 10.3109/01443615.2014.960827</mixed-citation></ref></ref-list></back></article>
